
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics has demonstrated promising clinical results for elraglusib in treating first-line metastatic pancreatic adenocarcinoma, with data showing significant improvements in median overall survival (mOS) and one-year survival rates compared to standard treatments. The company's recent fundraising has strengthened its balance sheet, enabling management to explore regulatory pathways without financial constraints while funding operational costs associated with upcoming clinical studies. Given the potential for elraglusib to achieve a positive regulatory decision with further validation in larger trials, optimism remains high regarding the company's future growth and development prospects.
Bears say
Actuate Therapeutics Inc is currently in the clinical stage of drug development with elraglusib targeting difficult-to-treat cancers, but recent financial reports indicate a concerning trend of increasing operational expenses that may outpace revenue growth. Additionally, the company faces significant risks associated with clinical trial outcomes and regulatory approvals, which could further strain its financial position due to the high costs of research and development. Lastly, limited market presence and potential competition in the biopharmaceutical sector heighten the uncertainty surrounding the viability and commercial success of its therapeutic candidates.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares